This study surveyed 2,800 Canadians about their views on using psilocybin (a psychedelic compound from certain mushrooms) to help patients with terminal illnesses manage existential distress and anxiety. About 79% of respondents thought it was a reasonable medical option, and 85% believed the government should cover the costs. People who had previous experience with psilocybin, those exposed to palliative care, and those with progressive political views were most supportive of this therapy.